NEWCELX LTD (NCEL) Stock Price & Overview
NASDAQ:NCEL • CH1442297896
Current stock price
The current stock price of NCEL is 3.35 USD. Today NCEL is down by -13.44%. In the past month the price increased by 78.19%.
NCEL Key Statistics
- Market Cap
- 15.276M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -20.39
- Dividend Yield
- N/A
NCEL Stock Performance
NCEL Stock Chart
NCEL Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NCEL.
NCEL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NCEL. NCEL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NCEL Earnings
NCEL Forecast & Estimates
NCEL Financial Highlights
Over the last trailing twelve months NCEL reported a non-GAAP Earnings per Share(EPS) of -20.39. The EPS increased by 69.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -143.26% | ||
| ROE | -215.58% | ||
| Debt/Equity | 0 |
NCEL Ownership
NCEL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.33 | 349.666B | ||
| AMGN | AMGEN INC | 14.87 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.62 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.08 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.61 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.26 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 11.37 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 24.944B | ||
| INCY | INCYTE CORP | 10.7 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NCEL
Company Profile
NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.
Company Info
IPO: 2021-01-29
NEWCELX LTD
The Circle 6
Zurich ZUERICH CH
Employees: 1
Phone: 41445122150
NEWCELX LTD / NCEL FAQ
What does NCEL do?
NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The firm offers products like Quilience, which is a clinical-stage pharmaceutical compound. The company aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The firm also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The firm is a publicly traded company, listing on the NASDAQ.
Can you provide the latest stock price for NEWCELX LTD?
The current stock price of NCEL is 3.35 USD. The price decreased by -13.44% in the last trading session.
Does NCEL stock pay dividends?
NCEL does not pay a dividend.
What is the ChartMill rating of NEWCELX LTD stock?
NCEL has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for NEWCELX LTD?
NEWCELX LTD (NCEL) operates in the Health Care sector and the Biotechnology industry.